| Cat. No. |
Product Name |
Information |
| PC-70305 |
3M-011
TLR7/8 agonist
|
3M-011 is a potent TLR7/8 agonist and cytokine inducer. |
| PC-70304 |
3M-003
TLR7/8 agonist
|
3M-003 is a potent TLR7/8 agonist that induces robust production of the Th1-polarizing cytokines TNF-alpha and IL-12 from neonatal antigen-presenting cells (APCs). |
| PC-70303 |
PF-4878691
TLR7 agonist
|
PF-4878691 (PF-04878691, S32865, 3M-852A) is a selective TLR7 agonist that potently induces IFN-α and IFN-regulated proteins from human PBMC. |
| PC-70302 |
3M-002
TLR8 agonist
|
3M-002 (CL-075) is a selective TLR8 agonist that induces activation of NF-κB at 0.4 uM. |
| PC-61096 |
TLR9 inhibitor 18
TLR9 inhibitor
|
TLR9 inhibitor 18 is a potent, selective TLR9 antagonist with IC50 of 13 nM (human TLR9), displays 75-fold selectivity over TLR7 and no activity against TLR8 (IC50>10 uM). |
| PC-61095 |
CPG-52364
TLR7/8/9 antagonist
|
CPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.. |
| PC-60332 |
CU-CPT9b
TLR8 inhibitor
|
CU-CPT9b (TLR8 inhibitor 9b) is a potent, selective TLR8 inhibitor with IC50 of 0.7 nM, Kd of 21 nM, and negligible cytotoxicity. |
| PC-60331 |
CU-CPT9a
TLR8 inhibitor
|
CU-CPT9a (TLR8 inhibitor 9a) is a potent, selective TLR8 inhibitor with IC50 of 0.5 nM, and negligible cytotoxicity. |
| PC-60002 |
CU-CPT8m
TLR8 inhibitor
|
CU-CPT8m is a novel potent, selective TLR8 inhibitor with Kd of 220 nM and IC50 of 67 nM, with negligible cytotoxicity. |
| PC-42165 |
TL2-C29
TLR2 inhibitor
|
TL2-C29 (TLR2 inhibitor C29) is a small molecule TLR2 inhibitor that blocks hTLR2/1 and hTLR2/6 signaling with IC50 of 19.7 uM and 37.6 uM, respectively, in NF-κB reporter assay in HEK293T cells. |
| PC-23645 |
TH-407b
TLR7 inhibitor
|
TH-407b is a potent and selective TLR7 inhibitor, dose-dependently inhibits R848-induced TLR7 activation with IC50 of 0.23 uM in HEK-Blue hTLR7 cells. |
| PC-22807 |
LHC165
TLR7 agonist
|
LHC165 is a potent, selective TLR7 agonist, generates effective tumor antigen-specific T-cell adaptive immune response as well as durable antitumor responses. |
